Research in Drug Development against Viral Diseases of Military Importance (Biological Testing)
Abstract
The purpose of this program is to evaluate the efficacy of candidate antiviral compounds against a spectrum of viruses of military importance. This program involves (a) primary testing of chemical compounds and natural products for antiviral efficacy in vitro using CPE-inhibition and plaque-reduction assays, (b) primary testing of compounds for antiviral efficacy in vivo in animal model systems, and (c) secondary evaluation of the active candidate antiviral compounds. The target viruses for in vitro testing are Vaccinia Virus (VV), Adenovirus (AD2), Vesicular Stomatitis Virus (VSV), Punta Toro Virus (PT), Sandfly Fever Virus (SF), Yellow Fever Virus (YF), Venezuelan Equine Encephalomyelitis Virus (VEE), Japanese Encephalitis Virus (JE), Pichinde Virus (PIC), and Hantaan Virus (HTN). The current in vivo systems are Pichinde Virus infection of hamsters, Venezuelan Equine Encephalomyelitis Virus, Japanese Encephalitis Virus and Vaccinia Virus infections of mice. Over 2600 compounds have been received for in vitro evaluation and over 14,000 assays have been performed on this contract to date. Compounds have been identified in nearly all virus systems that have confirmed antiviral activity exceeding that of the various positive control compounds (Ribavirin, Selenazole, and Ara-A). Many of these compounds represent potent and selective new antiviral agents.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 15, 1988
- Accession Number
- ADB148205
Entities
People
- A. D. Brazier
- B. R. Toyer
- B. Roberts
- E. A. Dulmadge
- G. Arnett
- L. J. Wilkoff
- L. Westbrook
- M. G. Hollingshead
- W. M. Shannon
Organizations
- Southern Research